Form 4: Regulus Therapeutics Director, David Baltimore, Acquires 30,000 Stock Options

Director David Baltimore acquired 30,000 stock options in Regulus Therapeutics Inc. on May 16, 2024, according to a Form 4 filing.

Summary

• David Baltimore, a director of Regulus Therapeutics Inc., acquired 30,000 stock options on May 16, 2024.
• The options have an exercise price of $2.01.
• These options were granted pursuant to the company's Non-Employee Director's Compensation policy.
• The options vest ratably over twelve months, becoming fully vested one year after the grant date or at the next annual stockholder meeting, contingent upon continuous service.
• Following the transaction, Baltimore directly owns 30,000 derivative securities.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing detailing a stock option grant to a director. It doesn't inherently convey strong positive or negative sentiment, but the grant itself can be seen as a moderate positive as it aligns director and shareholder interests.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service and commitment from the director.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for directors in publicly traded companies, particularly in the biotechnology sector.
• The vesting schedule of twelve months is fairly standard for director stock options.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign, aligning the director's interests with the company's long-term success.

Key Dates